Search results
How Horizon Therapeutics sold to Amgen for $27.8 billion without ever licensing a drug of its own
Fortune via Yahoo Finance· 1 year agoThe new drug looked so promising—except for that one warning sign. At the American College of...
FTC Sues Over Amgen’s $28 Billion Horizon Therapeutics Deal
Bloomberg via Yahoo News· 12 months ago(Bloomberg) -- The Federal Trade Commission sued to block Amgen Inc.’s $27.8 billion deal to buy...
John Paulson's Strategic Moves: Horizon Therapeutics PLC Takes the Lead with 16.59% Portfolio Impact
GuruFocus.com via Yahoo Finance· 6 months agoPaulson & Co. Adjusts Holdings in Q3 2023, Revealing Key Investment Decisions John Paulson (Trades,...
Amgen’s $27.8 Billion Horizon Takeover Allowed in FTC Accord
Bloomberg via Yahoo Finance· 8 months ago(Bloomberg) -- Amgen Inc. can move forward with its $27.8 billion takeover of Horizon Therapeutics...
Sensient Technologies Corp's Dividend Analysis
GuruFocus.com via Yahoo Finance· 6 months agoSensient Technologies Corp (NYSE:SXT) recently announced a dividend of $0.41 per share, payable on 2023-12-01, with the ex-dividend date set for...
PRIMECAP Management Bolsters Stake in Biomarin Pharmaceutical Inc
GuruFocus.com via Yahoo Finance· 3 months agoOn the last day of 2023, PRIMECAP Management (Trades, Portfolio) made a notable addition to its...
Weekly Upgrades and Downgrades
InvestorPlace via Yahoo Finance· 2 years agoDuring these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking...
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
Zacks via Yahoo Finance· 1 year agoLaunched on 10/13/2020, the Invesco NASDAQ Next Gen 100 ETF (QQQJ) is a passively managed exchange...
2 Marijuana Stocks That Are Set for a Comeback
Motley Fool· 2 years agoMarijuana stocks have been on a roller coaster ride lately. A combination of mixed legalization rules across states, the continued illegality of...
2 Supercharged Stocks to Buy With $100
Motley Fool· 11 months agoIt's important to take a look at the company's long-term prospects and its path to get there. The other is an innovative biotech with potentially...
